Chikungunya virus, a re-emerging mosquito-borne alphavirus, causes fever, rash and persistent arthralgia/arthritis in humans. Severe outbreaks have occurred resulting in infections of millions of people in Southeast Asia and Africa. Currently there are no antiviral drugs or vaccines for prevention and treatment of chikungunya infections. Herein we report the current status of research on antiviral drugs and vaccines for chikungunya virus infections.
Introduction
Chikungunya virus (CHIKV) is an arthropodborne virus belonging to the Family, Togaviridae, and genus, Alphavirus. In this group of 29 viruses, six cause arthralgia and arthritis upon infection in humans. These six viruses are CHIKV, Ross River virus (RRV), Semliki Forest virus (SFV), o'nyongnyong virus (ONNV), Sindbis virus (SINV) and Mayaro virus (MAYV). CHIKV was first isolated from a febrile patient in Tanzania in 1952 1 . The name chikungunya means "that which bends up" and refers to the contorted posture adopted by infected patients. Symptomatic CHIKV infections are characterised by fever, rashes and arthralgia leading to arthritis. In the last 50 years there have been frequent outbreaks of CHIKV disease in Asia and Africa. In 2005-2006 Currently there are no vaccines or antivirals for the prevention or treatment of CHIKV infections. Treatment is symptomatic with analgesics, antipyretics and non-steroidal anti-inflammatory agents. Passive immunization with human IgGs derived from CHIKV infected patients has been shown to be protective in mice against CHIKV challenge 5 . This approach may prove effective for the prevention and treatment of neonates who are at the risk of infection from viraemic mothers. However, this is not cost-effective and it is critical to develop antiviral drugs and/or vaccines for the control of CHIKV infections.
Owing to the recent outbreaks of CHIKV in Asia, Africa and La Réunion island there has been a renewed interest in the development of antiviral drugs and vaccines to manage CHIKV infections. In this article, we report on the advancements made towards the development of anti-inflammatory agents, antivirals and vaccines for the efficient control of CHIKV infections.
Antiviral compounds
Chloroquine phosphate was reported to be effective in the treatment of chronic CHIKV arthritis 6 . However, in a clinical trial of chloroquine in CHIKV infected patients, no difference was observed between the placebo group and the treatment group 7 . Maheshwari et al 8 have also reported that in a mouse model, chloroquine enhances alphavirus replication and aggravates disease pathogenesis. Ribavirin, an antiviral agent was used to treat CHIKV induced arthritis in a small cohort of patients and was found to be beneficial in resolving joint and soft tissue swelling An additional 356 compounds (natural and clinically approved drugs) were initially screened for their antiviral effects using a CHIKV replicon cell line 13 . A recombinant CHIKV with Rluc (Renilla luciferase) fused with nonstructural protein 3 (CHIKVRluc) was constructed and used to validate the most active compounds from the initial screening studies. Out of 12 selected compounds, coumarin 30 was found to be the most potent in inhibiting the replication of CHIKV-RLuc virus (IC 50 value of 6.4 µM). Arbidol, licensed for the treatment of influenza and other respiratory infections, was found to be effective in inhibiting CHIKV replication in Vero and MRC-5 cell lines (IC 50 <10µg/ml) 14 . Recently, screening of a highly purified natural compound library for inhibition of CHIKV replication identified 44 inhibitors
15
. Among the selected compounds, harringtone, a cephalotoxine alkaloid, was found to be a potent inhibitor of CHIKV infection with an EC 50 value of 0.24 µM. This drug was found to inhibit the early stages of CHIKV replication. As this was also found to inhibit SINV replication suggesting the drug may be effective against other alphaviruses. In another study, an optimal homology model of CHIKV nonstructural protein 2(nsp2) protease was created using comparative modelling approach. Based on the active site of nsP2 model, a virtual screening was performed with commercially available compounds subsequently 26 compounds were evaluated for the anti-CHIKV activity in a cell culture assay 16 . . Immunization with VLPs and DNA vaccines resulted in immunogenicity and protected the mice and non-human primates against subsequent challenge with CHIKV.
Vaccines
Chimaeric viruses containing Venezeulean equine encephalitis virus (VEEV) or Eastern equine encephalitis virus (EEEV) or SINV non-structural proteins with CHIKV structural proteins elicited neutralizing antibodies and protected the mice against CHIKV challenge 23 . However, these viruses still had the ability to infect mosquitoes and attenuation was dependent on an intact interferon response in mice. Another chimaeric vaccine using VEEV strain TC-83 and encepahalomyocarditis virus (EMCV) IRES (internal ribosome entry site) in the subgenomic promoter was developed to reduce the transmission to mosquitoes. The EMCV IRES sequence cannot efficiently drive translation in arthropod cells. This vaccine was poorly immunogenic and lacked neutralizing antibody response 24 . Recently Chattopadhyay et al 25 developed a chimaeric vaccine using a vesiculostomatitis virus (VSV) backbone and CHIKV structural proteins (VSV∆G-CHIKV). This VSV∆G-CHIKV chimaeric virus induced a good neutralizing antibody response and protected mice against CHIKV infection.
Plante et al
24 designed a vaccine by introducing the EMCV IRES sequence into the CHIKV subgenomic promoter. This reduced the replication of the vaccine strain in mosquitoes and was highly immunogenic in mice. This vaccine is now undergoing preclinical trials in non-human primates.
Short interfering RNA (siRNA) and short hairpin RNAs (shRNA) siRNAs and shRNAs against envelope protein E1, nsP3, capsid and nsP1 proteins of the CHIKV have been used to inhibit the replication of CHIKV in mammalian cells with promising results 26, 27 . Furthermore, in vivo studies have shown that shRNA E1 offers a strong and sustained protection against CHIKV infection in suckling mice.
Other therapeutic options
Studies on the role of mannose binding lectin (MBL) in RRV-induced arthritis in mice 28 suggest that MBL may be a target for therapeutic intervention in the treatment of alphavirus induced arthritis/myositis. Inhibitors targeting the MBL pathway of complement may be useful in the treatment of alphavirus induced diseases. Additionally, a peptide corresponding to the autophagy inducing peptide, beclin, has been shown to be effective against CHIKV infections in cell culture and in mice 29 .
A recent study on gene profiling has revealed a significant overlap of differentially expressed genes involved in the inflammatory processes of both CHIKVinduced arthritis and rheumatoid arthritis (RA). Thus, new drugs being developed for RA might also be beneficial for the treatment of alphavirus induced arthritis 30 .
Conclusions
Chikungunya fever is a global health problem and several outbreaks have occurred in the last 50 years in Asia and Africa. Recent outbreaks in La Réunion and Italy have raised the awareness of the need to develop effective antiviral drugs or vaccines against CHIKV. Although many antiviral compounds have been shown to be effective in cell culture, very few compounds have been evaluated in animal models. Intensive studies are needed to evaluate the effect of appropriate compounds in animal models and humans.
